314 related articles for article (PubMed ID: 36176403)
1. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Xu Y; Fu S; Shang K; Zeng J; Mao Y
Front Oncol; 2022; 12():958869. PubMed ID: 36176403
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.
Xu Y; Fu S; Liu K; Mao Y; Wu J
Ther Clin Risk Manag; 2023; 19():853-863. PubMed ID: 37899984
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
4. A multi-center retrospective study on the efficacy and safety of regorafenib
Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
[TBL] [Abstract][Full Text] [Related]
7. Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib
Mei J; Tang YH; Wei W; Shi M; Zheng L; Li SH; Guo RP
Front Oncol; 2021; 11():618206. PubMed ID: 33718175
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.
Liu K; Wu J; Xu Y; Li D; Huang S; Mao Y
Onco Targets Ther; 2022; 15():1079-1094. PubMed ID: 36212725
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
Wei F; Huang Q; He J; Luo L; Zeng Y
Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
[TBL] [Abstract][Full Text] [Related]
11. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
Chang X; Li X; Sun P; Li Z; Sun P; Ning S
BMC Cancer; 2024 Apr; 24(1):480. PubMed ID: 38627684
[TBL] [Abstract][Full Text] [Related]
12. Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.
Falette-Puisieux M; Nault JC; Bouattour M; Lequoy M; Amaddeo G; Decaens T; Di Fiore F; Manfredi S; Merle P; Baron A; Locher C; Pellat A; Coriat R
Ther Adv Med Oncol; 2023; 15():17588359231189425. PubMed ID: 37547443
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.
Terashima T; Yamashita T; Takata N; Takeda Y; Kido H; Iida N; Kitahara M; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2021 Feb; 51(2):190-200. PubMed ID: 33197087
[TBL] [Abstract][Full Text] [Related]
15. Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma.
Huang JX; Liu B; Li Y; Li X; Ding LJ; Wang NY
Front Oncol; 2023; 13():1204486. PubMed ID: 37664019
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis.
Luo J; Gao B; Lin Z; Fan H; Ma W; Yu D; Yang Q; Tian J; Yang X; Li B
Front Oncol; 2022; 12():1010726. PubMed ID: 36620586
[TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.
Chiang HC; Lee YC; Chang TT; Lin YJ; Wu HT; Wang CT; Chen CY; Chen PJ; Hsieh MT; Lin SH; Chen SH; Chuang CH; Wu IC; Hong TC; Wu JS; Han MZ; Chen WT; Chiang CM; Hung KK; Kuo HY
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765812
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD
Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World.
Li X; Fu Z; Chen X; Cao K; Zhong J; Liu L; Ding N; Zhang X; Zhai J; Qu Z
Front Oncol; 2022; 12():950266. PubMed ID: 35860582
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma.
Xu Y; Fu S; Mao Y; Huang S; Li D; Wu J
Front Med (Lausanne); 2022; 9():919069. PubMed ID: 36117969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]